In Brief: IND Applications For Cosmetic Trials? Lauder Appointment; P&G At Olympics
This article was originally published in The Rose Sheet
Comments may be submitted through April 7 regarding cosmetics-related sections in an FDA guidance that could impose the costs and burden of Investigational New Drug application on beauty companies conducting clinical trials. More news in brief.
You may also be interested in...
Unilever reports a 3% decline in FY 2013 turnover, but underlying sales growth was ahead of market, the firm says, crediting strong innovation in personal care and successes in emerging markets, among other factors. Going forward the firm aims to create efficiencies via SKU reductions and other streamlining efforts.
An FDA guidance document intended to clarify if firms conducting certain drug studies involving human subjects are obligated to file Investigational New Drug Applications instead raises questions for the cosmetics industry.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.